Latest Licensing News

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

PlaySide Studios reversed a prior-year loss with a 13% revenue increase to $54.9 million and a 144% jump in net profit to $5.4 million, driven by strong Original IP sales and a strategic cost restructure.

Super Retail Group reported a 3.2% revenue increase to $4.2 billion in FY26, but statutory net profit fell 7.2% to $206 million amid higher costs and project investments. A new five-year strategy aims to drive growth despite a challenging retail environment.

Yowie Group's revenue declined in the first half of 2026 as it navigated supply chain shifts and cautious retail demand, but the company secured a significant Australian licensing deal and ended costly legacy litigation.

InvestSMART Group Limited swung to a net loss of $575,633 in FY26, marking a sharp reversal from the prior year’s profit, amid a strategic pivot including a pending $16 million sale of its Intelligent Investor business.

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.

Mount Ridley Mines has lodged a provisional patent for its SelectroTM hydrometallurgical leach technology, demonstrating superior recoveries of rare earths, scandium, and gallium compared to conventional methods. The company is advancing testwork and commercial discussions to capitalise on the innovation.

Atomo Diagnostics has appointed Dr Cheri Walker as interim CEO, replacing founder John Kelly who steps down after 15 years. The leadership change aligns with the company's shift towards commercial growth in the US and Europe.

Patriot Resources has locked in a $3 million placement to fund exploration at its flagship Tassa silver-gold project in Peru and a new copper discovery in Zambia, underpinning its strategy to grow high-grade mineral resources.

Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.

Critical Resources has bolstered its Mavis Lake lithium project by staking new claims at the Red Hat gold target in Ontario, spotlighting a historical high-grade gold intercept that sharpens exploration focus.

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.